Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method

Ippei Fujimori, Akira Saito, Ichiro Nakayama, Masumi Tomisawa, Kazuo Takebe, Mitsuo Nakamura, Takahiko Kawagishi, Tadashi Miyazawa, Toyokazu Tamura, Katsumi Endo, Tamotsu Takishima, Ruriko Mamune, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Akira Watanabe, Yutaka Tokue, Izumi Hayashi, Shinji Okui, Toshio FukuiShinjiro Kato, Osamu Hosono, Toru Abe, Toshihiko Haga, Harumi Shishido, Hiroyuki Kobayashi, Shin Kawai, Hiroaki Takeda, Masahide Kawahira, Tadashi Miyahara, Jingoro Shimada, Junzaburo Kabe, Koichiro Kudo, Yoshio Sakamoto, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Koji Yoshimoto, Hideo Ikemoto, Kazuyoshi Watanabe, Masayoshi Inagaki, Hajime Orimo, Yoshinosuke Fukuchi, Minoru Yamaoka, Mitsuo Honma, Takashi Kawai, Atsushi Ajisawa, Akio Onaka, Fuyuhiko Higashi, Kazumi Arikawa, Tatsuo Kato, Miyoko Kuramoto, Hiroichi Tanimoto, Koichiro Nakata, Naohiko Chonabayashi, Yoshitaka Nakamori, Tatsuo Nakatani, Takashi Inamatsu, Makiko Fukayama, Kentaro Watanabe, Masaru Koyama, Yoshio Uzuka, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Takeshi Mitsui, Takao Okubo, Hirotada Ikeda, Masanori Matsumura, Hiroshi Takahashi, Fumio Matsumoto, Iwao Sakurai, Kazufuto Fukaya, Shigeki Odagiri, Kaneo Suzuki, Kohu Murohashi, Keiichiro Matsunaga, Hiroyuki Numata, Izumi Oyama, Shunichi Ishii, Masaaki Arakawa, Koichi Wada, Osamu Sekine, Nobuki Aoki, Kaoru Oyama, Atsuhiko Sato, Masahiko Okano, Wataru Sugiura, Akira Yamazaki, Takayoshi Watanabe, Toshihiko Takeuchi, Masahito Kato, Kunio Nanjo, Tatsuo Satake, Kenzo Takagi, Kenichi Yamaki, Hideo Gonda, Yasunobu Noda, Fumiyuki Kuze, Takuya Kurasawa, Takako Murayama, Eisaku Tanaka, Takakazu Sugita, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shinichi Tanizawa, Kazuo Sakamoto, Akira Tahara, Yoshio Kawase, Kojiro Yasunaga, Seibun Yonezu, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Yoshikazu Tasaka, Toshio Kishimoto, Toshiharu Matsushima, Michifumi Adachi, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Takao Sasaki, Yukio Matsumoto, Yoshiro Sawae, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Hozumi Yamada, Osamu Katoh, Kohei Hara, Masaki Hirota, Keizo Yamaguchi, Shigeru Kohno, Toshiaki Hayashi, Akira Yasuoka, Kazuo Sasayama, Makoto Ishizaki, Takashi Ide, Hiroko Nakazato, Oe Toshiyuki, Keizo Matsumoto, Atsushi Takahashi, Sukuro Araki, Masayuki Ando, Moritaka Suga, Kiyoshi Shima, Shinobu Takenaka, Yasutsugu Fukuda, Haruhiko Tokuomi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Takayoshi Tashiro

    Research output: Contribution to journal › Article › peer-review

    11 Citations (Scopus)

    Abstract

    We compared the clinical efficacy, safety and utility of T-3262 (tosufloxacin tosilate), a new derivative pyridonecarboxylic acid, with those of ofloxacin (OFLX) in patients with respiratory tract infection (RTI) by double-blind study. RTI included in the protocol were bacterial pneumonia and chronic respiratory tract infection. The drug was given orally for a fixed period of 14 days and the daily dosage was fixed at 450mg for T-3262 or 600mg for OFLX. The following results were obtained. 1. On the basis of committee judgement, the clinical efficacy rate in all cases was 82.9% for T-3262 and 82.5% for OFLX. No significant difference was observed between the two groups, not even in clinical efficacy when classified by type of disease. 2. The clinical efficacy rate judged by the doctors in charge was similar to that judged by the committee. 3. The bacteriological eradication rate of causative organisms judged by the committee was 78.6% for T-3262 and 85.1% for OFLX, without statistically significant difference. 4. With respect to the rate of improvement of clinical signs, symptoms and laboratory findings, T-3262 was superior to OFLX as to body temperature. 5. The incidence rate of side effects was 7.8% for T-3262 and 6.7% for OFLX, and there were no significant differences between the two groups. Abnormalities in laboratory findings, mainly slightly elevated serum transaminase and eosinophils, were not significantly different between the two groups. 6. The utility rate in all cases judged by the committee was 79.6% for T-3262 and 79.8% for OFLX. No significant difference between the two groups was noted. Even when classified by type of disease, there was no significant difference in utility between the two groups. 7. Neither was there any significant difference between the two groups in the utility rate when judged by the doctors in charge. 8. From our results, we consider both T-3262 (at a daily dose of 450 mg) and OFLX (at a daily dose of 600mg) to be highly useful antibacterial agents for the treatment of respiratory tract infections.

    Original languageEnglish
    Pages (from-to)1086-1118
    Number of pages33
    JournalChemotherapy
    Volume37
    Issue number8
    DOIs
    Publication statusPublished - 1989

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    UN SDGs

    This output contributes to the following Sustainable Development Goal(s)

    • SDG 3 - Good Health and Well-being

    Access to Document

    Other files and links

    Fingerprint Dive into the research topics of 'Comparative study on T-3262 (tosufloxacin tosilate) and ofloxacin in respiratory tract infection by double-blind method'. Together they form a unique fingerprint.

    Cite this